News | February 23, 2022
Agilent posts Q1 FY2022 revenue at US$ 1.67 billion
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Ind-Ra expects revenue growth of over 12% in 2022.
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
